Title of study

    The Swedish BioFINDER study

    Acronym for cohort

    BioFINDER

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Oskar

    Name of Principal Investigator - Last name

    Hansson

    Address of institution -Institution

    Lund University

    Address of institution - Street address

    Address of institution - City

    Address of institution - Postcode

    Country

    Sweden

    Website
    Contact email
    Funding source

    ECR, SRC, Wallenberg etc

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias| Parkinson's disease

    Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

    To development of new biomarkers and brain imaging techniques for Dementia and Parkinsonian disorders with the aim to better understand the diease mechanisms, to improve early diagnosis and to advance drug development.

    Q2b. What distinguishes this case-control study from other studies?

    The BioFINDER study is a prospective and longitudinal study where the studye partcipanst are very well characterised using assessmenst oc cogntive, neurologic and psychitric status, advanced MR imaging, CSF and blood collection, and PET imaging for amyloid and tau. Few such studies are availabel in teh world, why the pharma industry has a high interest in teh study.

    Q3a. i) Number of publications that involve use of your cohort to date

    40

    Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

    Oskar Hansson, Lund University, Increased amyloidogenic APP processing in APOE ?4-negative individuals with cerebral ?-amyloidosis| Oskar Hansson, Lund University, 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers| Oskar Hansson, Lund University, Comparison of Amyloid PET and CSF Biomarkers for Identifying Early Alzheimer’s Disease.

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    http://biofinder.se/publications/

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    65

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    until death

    Q4b. Study criteria: what are the inclusion criteria?

    see www.biofinder.se for details

    Q4c. Study criteria: what are the exclusion criteria?

    see www.biofinder.se for details

    Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

    1,000-5,000

    Q5b. What is the expected number of control participants?

    1,001-5,000

    Q6a. Please describe what measures are used to characterise participants

    Q6b. Are there additional measures for participants with the clinical disorder?

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    If YES please specify

    Q7. What is the study design?

    Prospective cohort

    Q8. Are your cases matched by

    Age| Sex

    Q9a. Does your study includes a specialised subset of control participants?

    Yes

    Q9b. If your study includes a specialised subset of control participants please describe

    350 healthy elderly cases with cognitive testing, MRI, CSF biomarkers, blood biomarkers, Amyloid PET and some also Tau PET

    Q10a. Is data collection for this study

    Data collection ongoing| Data analysis ongoing| Closed to new patients

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - intend to apply for funding

    Q11. Are data collected

    Only through study

    Q12. Is there a system in place to enable re-contact with patients for future studies?

    Q13a. Please give information on data stored in a database (1)

    Data summarised in database

    % Available

    100

    Q13a. Please give information on data stored in a database (2)

    No

    % Available

    Q13a. Please give information on data stored in a database (3)

    Database on spreadsheet (e.g. excel)

    % Available

    100

    Q13a. Please give information on data stored in a database (4)

    No

    % Available

    Q13a. Please give information on data stored in a database (5)

    No

    % Available

    Please specify language used

    100% of baseline data, but longitudinal data is still colllected

    % Available

    Q13b. Please give information on how data is held as individual records

    No

    % Available

    Q14a. Are data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Access through collaboration with PI only| Local/ regional access| National access| International access| Access to industry| Access for pilot studies permitted

    Q15. What data sharing policy is specified as a condition of use?

    No requirement to make data publicly available

    Q16a. Are tissues/samples/DNA available to other groups?

    Yes

    Q16b i) If yes, please describe below

    Living donors: blood| Living donors: DNA| Living donors: cerebro-spinal fluid

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Secondary samples: plasma| Secondary samples: DNA

    Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Yes

    Q17. Is information on biological characteristics available to other groups?

    Yes, for all the cohort

Types: Case Control Studies
Member States: Sweden
Diseases: Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF